NASDAQ | ETF
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target.
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.
Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 8.14% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 7.41% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 7.21% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 6.12% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 5.67% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 4.13% |
| ALXN | Alexion Pharmaceuticals Inc | Healthcare | Biotechnology | 3.02% |
| SGEN | Seagen Inc | Healthcare | Biotechnology | 2.25% |
| INCY | Incyte Corporation | Healthcare | Biotechnology | 2.09% |
| BMRN | Biomarin Pharmaceutical Inc | Healthcare | Biotechnology | 1.91% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 1.60% |
| MYL | Viatris Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 1.35% |
| SNY | Sanofi ADR | Healthcare | Drug Manufacturers - General | 1.29% |
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 1.16% |
| SRPT | Sarepta Therapeutics Inc | Healthcare | Biotechnology | 1.15% |
| NVCR | Novocure Ltd | Healthcare | Medical Devices | 1.10% |
| JAZZ | Jazz Pharmaceuticals PLC | Healthcare | Biotechnology | 1.03% |
| IONS | Ionis Pharmaceuticals Inc | Healthcare | Biotechnology | 1.02% |
| TECH | Bio-Techne Corp | Healthcare | Biotechnology | 1.02% |
| GH | Guardant Health Inc | Healthcare | Diagnostics & Research | 0.96% |